^
    Back
    Association details:
    Biomarker:HER-2 overexpression
    Cancer:Breast Cancer
    Drug:Herceptin Hylecta (trastuzumab/hyaluronidase-oysk) (HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    HERCEPTIN HYLECTA is a combination of trastuzumab, a HER2/neu receptor antagonist, and hyaluronidase, an endoglycosidase, indicated in adults for...the treatment of HER2-overexpressing breast cancer.
    Secondary therapy:
    paclitaxel; carboplatin + docetaxel
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Feasibility Assessment of a Patients Follow-up Visit Receiving Trastuzumab Subcutaneous by Advanced Practice Nurse

    Excerpt:
    ...- Patient with breast cancer overexpressing HER2 adjuvant...
    Trial ID:
    TIPA